Views

CrossRef citations to date

Altmetric

Original Research

Tumor SQSTM1 (p62) expression and T cells in colorectal cancer

Keisuke KosumiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Yohei MasugiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Juhong YangCollaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China

Zhi Rong QianDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Sun A. KimLaboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Wanwan LiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Yan ShiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Annacarolina da SilvaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Tsuyoshi HamadaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Li LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Mancang GuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Tyler S. TwomblyDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Yin CaoDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA

David A. BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Katsuhiko NoshoDepartment of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan

Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan

Wendy S. GarrettDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Jeffery A. MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Edward L. GiovannucciDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Andrew T. ChanClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA;Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA;Broad Institute of MIT and Harvard, Cambridge, MA, USA

Charles S. FuchsDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA

Shuji OginoDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA;Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]

Reiko NishiharaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA;Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USACorrespondence[email protected]

show all

Figures & data

Table 1. Clinical, pathological, and molecular features of colorectal cancers according to tumor SQSTM1 (p62) expression level.

Download CSV Display Table

Table 2. Distribution of colorectal cancer cases according to tumor SQSTM1 expression level and the density of T cells.

Download CSV Display Table

Table 3. Ordinal logistic regression analysis to assess the association of tumor SQSTM1 expression level (predictor) with the density of T cells (outcome).

Download CSV Display Table

Figure 1. Tumor SQSTM1 (p62) expression in colorectal cancer. Tumor SQSTM1 expression was scored as low (A), intermediate (B), or high (C), according to cytoplasmic expression level of SQSTM1 in tumor cells.

Supplemental material

KONI_A_1284720_Supplementary_table_1.docx

Download MS Word (31.7 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Tumor SQSTM1 (p62) expression and T cells in colorectal cancer

Table 1. Clinical, pathological, and molecular features of colorectal cancers according to tumor SQSTM1 (p62) expression level.

Table 2. Distribution of colorectal cancer cases according to tumor SQSTM1 expression level and the density of T cells.

Table 3. Ordinal logistic regression analysis to assess the association of tumor SQSTM1 expression level (predictor) with the density of T cells (outcome).

KONI_A_1284720_Supplementary_table_1.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tumor SQSTM1 (p62) expression and T cells in colorectal cancer

Figures & data

Table 1. Clinical, pathological, and molecular features of colorectal cancers according to tumor SQSTM1 (p62) expression level.

Table 2. Distribution of colorectal cancer cases according to tumor SQSTM1 expression level and the density of T cells.

Table 3. Ordinal logistic regression analysis to assess the association of tumor SQSTM1 expression level (predictor) with the density of T cells (outcome).

KONI_A_1284720_Supplementary_table_1.docx

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date